Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the BRAF mutation

A 72-year-old male patient with advanced lung adenocarcinoma harboring a BRAF mutation had received treatment with a BRAF inhibitor and a MEK inhibitor. Treatment was ceased after 40 days because of disease progression. Twenty-four days after treatment cessation, the man was referred to our hospital...

Full description

Saved in:
Bibliographic Details
Published inRespiratory medicine case reports Vol. 36; p. 101608
Main Authors Watanabe, Hirofumi, Karayama, Masato, Inoue, Yusuke, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Inui, Naoki, Suda, Takafumi
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.01.2022
Elsevier
Subjects
Arterial thromboembolism
BRAF inhibitor
Case Report
MEK inhibitor
Oncogene
BRAF inhibitor
Arterial thromboembolism
MEK inhibitor
Oncogene
Online AccessGet full text

Cover

More Information
Summary:A 72-year-old male patient with advanced lung adenocarcinoma harboring a BRAF mutation had received treatment with a BRAF inhibitor and a MEK inhibitor. Treatment was ceased after 40 days because of disease progression. Twenty-four days after treatment cessation, the man was referred to our hospital with worsening abdominal and back pain over 2 weeks. Computed tomography revealed a massive thrombus in the descending aorta, bilateral kidney infarction, splenic infarction, and intestinal enlargement due to ileus. He was diagnosed with multiple organ infarction caused by arterial thromboembolism. Tumors harboring BRAF mutations and BRAF/MEK inhibitor therapy both have the potential to increase thrombosis risk, and were therefore thought to be associated with the occurrence of aortic thrombosis.
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2022.101608